LDL Receptor-Related Protein 2 (Megalin) as a Target Antigen in Human Kidney Anti-Brush Border Antibody Disease

Christopher P. Larsen, Claire Trivin-Avillach, Paige Coles, A. Bernard Collins, Michael Merchant, Hong Ma, Daniel W. Wilkey, Josephine M. Ambruzs, Nidia C. Messias, L. Nicholas Cossey, Ivy A. Rosales, Thomas Wooldridge, Patrick D. Walker, Robert B. Colvin, Jon Klein, David J. Salant, Laurence H. Beck

Research output: Contribution to journalArticlepeer-review

68 Scopus citations

Abstract

Primary renal tubulointerstitial disease resulting from proximal tubule antigen-specific antibodies and immune complex formation has not been well characterized in humans. We report a cohort of patients with a distinct, underappreciated kidney disease characterized by kidney antibrush border antibodies and renal failure (ABBA disease). We identified ten patients with ABBA disease who had a combination of proximal tubule damage, IgG-positive immune deposits in the tubular basement membrane, and circulating antibodies reactive with normal human kidney proximal tubular brush border. All but one of the patients also had segmental glomerular deposits on renal biopsy specimen. Patients with ABBA disease were elderly and presented with AKI and subnephrotic proteinuria. Serum from all patients but not controls recognized a high molecular weight protein in renal tubular protein extracts that we identified as LDL receptor-related protein 2 (LRP2), also known as megalin, by immunoprecipitation and mass spectrometry. Immunostaining revealed that LRP2 specifically colocalized with IgG in the tubular immune deposits on the ABBA biopsy specimen but not the control specimen analyzed. Finally, ABBA serum samples but not control samples showed reactivity against recombinantly expressed N-terminal LRP2 fragments on Western blots and immunoprecipitated the recombinantly expressed N-terminal region of LRP2. This case series details the clinicopathologic findings of patients with ABBA disease and shows that the antigenic target of these autoantibodies is LRP2. Future studies are needed to determine the disease prevalence, stimulus for ABBA, and optimal treatment.

Original languageEnglish
Pages (from-to)644-653
Number of pages10
JournalJournal of the American Society of Nephrology
Volume29
Issue number2
DOIs
StatePublished - Feb 2018

Fingerprint

Dive into the research topics of 'LDL Receptor-Related Protein 2 (Megalin) as a Target Antigen in Human Kidney Anti-Brush Border Antibody Disease'. Together they form a unique fingerprint.

Cite this